别名 Janus激酶1、JAK-1、JAK1 + [5] |
简介 Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway (PubMed:8232552, PubMed:7615558, PubMed:28111307, PubMed:32750333, PubMed:16239216). Kinase partner for the interleukin (IL)-2 receptor (PubMed:11909529) as well as interleukin (IL)-10 receptor (PubMed:12133952). Kinase partner for the type I interferon receptor IFNAR2 (PubMed:8232552, PubMed:7615558, PubMed:28111307, PubMed:32750333, PubMed:16239216). In response to interferon-binding to IFNAR1-IFNAR2 heterodimer, phosphorylates and activates its binding partner IFNAR2, creating docking sites for STAT proteins (PubMed:7759950). Directly phosphorylates STAT proteins but also activates STAT signaling through the transactivation of other JAK kinases associated with signaling receptors (PubMed:8232552, PubMed:16239216, PubMed:32750333). |
作用机制 ALK2抑制剂 [+2] |
非在研适应症 |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2023-09-15 |
靶点 |
作用机制 JAK1抑制剂 |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 欧盟 [+3] |
首次获批日期2020-09-24 |
开始日期2024-12-31 |
申办/合作机构 |
开始日期2024-12-01 |
申办/合作机构 |
开始日期2024-07-31 |